Potential neurotoxic effects of gadopentetate dimeglumine: clinical significance.
Alhassan
A
A
Weinmann
H J
HJ
D000367:Age Factors; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000187:drug effects*; D002675:Child, Preschool; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D004195:Disease Models, Animal; D004338:Drug Combinations; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects*; D019786:Gadolinium DTPA; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007278:Injections, Spinal; D007454:Iodides / Q000008:administration & dosage / Q000009:adverse effects; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D004369:Pentetic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D051381:Rats
D003287:Contrast Media; D004338:Drug Combinations; D007454:Iodides; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA